Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy-Reference-Cited by-同舟云学术

Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy

Published:2022-03-09 Issue:5 Volume:63 Page:1276-1278
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:Epilepsia

Author:

Noyman Iris¹²,Ekstein Dana³⁴^ORCID,Fahoum Firas⁵⁶^ORCID,Herskovitz Moshe⁷⁸^ORCID,Linder Ilan⁹,Ben Zeev Bruria⁶¹⁰,Eyal Sara¹¹^ORCID

Affiliation:

1. Pediatric Neurology Unit Soroka University Medical Center Beer Sheva Israel

2. Faculty of Health Sciences Ben‐Gurion University of the Negev Beer Sheva Israel

3. Department of Neurology Agnes Ginges Center of Human Neurogenetics Hadassah Medical Organization Jerusalem Israel

4. Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel

5. Epilepsy and EEG Unit, Neurology Division Tel Aviv Sourasky Medical Center Tel Aviv Israel

6. Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

7. Department of Neurology Rambam Health Care Campus Haifa Israel

8. Technion Faculty of Medicine Haifa Israel

9. Pediatric Epilepsy and Neurology Service Barzilai Medical Center Ashkelon Israel

10. Pediatric Neurology Unit Safra Pediatric Hospital Sheba Medical Center Tel Hashomer Israel

11. Institute for Drug Research School of Pharmacy Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/epi.17212

Reference11 articles.

1. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. Revised 2021 Dec 22 [cited 2021 Feb 18]. Available from:https://www.FDA.gov/media/155050/download

2. Israel Ministry of Health. תרופות נגד קורונה ‐ פייזר .2021 Dec 30 [cited 2022 Jan 20]. Available from:https://www.gov.il/he/departments/policies/medical‐treatment

3. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans

4. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies

5. Dose–Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A cross-sectional study on the potential drug-drug interaction risk of COVID-19 patients in hospital;Int. Journal of Clinical Pharmacology and Therapeutics;2024-07-01

2. High concentrations of nirmatrelvir/ritonavir in critically ill patients receiving continuous renal replacement therapy;International Journal of Antimicrobial Agents;2024-01

3. The extent of cytochrome P450 3A induction by antiseizure medications: A systematic review and network meta‐analysis;Epilepsia;2023-12-11

4. Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19;Expert Review of Anti-infective Therapy;2023-08-01

5. Pharmacological aspects of antiseizure medications: From basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring;Epileptic Disorders;2023-06